Man Group plc Raises Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Man Group plc boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 76.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,597 shares of the biopharmaceutical company’s stock after acquiring an additional 21,098 shares during the quarter. Man Group plc’s holdings in Intra-Cellular Therapies were worth $4,059,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Nicholas Investment Partners LP lifted its holdings in Intra-Cellular Therapies by 14.3% in the 4th quarter. Nicholas Investment Partners LP now owns 176,870 shares of the biopharmaceutical company’s stock worth $14,772,000 after buying an additional 22,072 shares during the period. Nuveen Asset Management LLC lifted its holdings in Intra-Cellular Therapies by 6.4% in the 4th quarter. Nuveen Asset Management LLC now owns 519,253 shares of the biopharmaceutical company’s stock worth $43,368,000 after buying an additional 31,331 shares during the period. Occudo Quantitative Strategies LP purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth approximately $379,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Intra-Cellular Therapies by 17.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 20,284 shares of the biopharmaceutical company’s stock worth $1,694,000 after buying an additional 2,941 shares during the period. Finally, Orbimed Advisors LLC purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth approximately $13,614,000. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Thursday, May 15th. They issued a “hold” rating for the company. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Finally, Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Eleven research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Intra-Cellular Therapies has an average rating of “Hold” and an average price target of $109.70.

Intra-Cellular Therapies Price Performance

ITCI opened at $131.87 on Thursday. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The business has a 50 day moving average of $131.82 and a 200-day moving average of $114.77. Intra-Cellular Therapies, Inc. has a 52 week low of $64.72 and a 52 week high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.